Okay, so here’s the deal. Boxer Capital, which sounds suspiciously like a gym for hedge fund managers, just dropped $9.5 million on Tango Therapeutics (TNGX). That’s a lot of money. Like, enough to buy a small island and rename it “Boxer Capital Atoll.” They snagged over 1.1 million shares. February 17th, 2026, to be exact. Mark your calendars. Or don’t. I’m not your mother.
What Does This Even Mean?
Apparently, Boxer Capital really likes Tango. They increased their stake, bringing their total holdings to a cool 21.09% of their 13F reportable AUM as of December 31st, 2025. AUM, for those of us who don’t speak fluent finance-ese, is Assets Under Management. It’s basically how much money they’re playing with. And they’re playing with a lot. The total value of their TNGX holdings now clocks in at $96.36 million. It’s like a really expensive game of Candy Crush.
Here’s a quick rundown of Boxer Capital’s top holdings, because transparency is so hot right now:
- NASDAQ:TNGX: $96.36 million (21.1% of AUM)
- NASDAQ:RVMD: $31.86 million (7.0% of AUM)
- NASDAQ:KOD: $31.76 million (7.0% of AUM)
- NASDAQ:KYMR: $25.61 million (5.6% of AUM)
- NASDAQ:CELC: $22.44 million (4.9% of AUM)
And get this: Tango Therapeutics stock is up 426.7% over the past year. That’s…a lot. It’s outperformed the S&P 500 by a staggering 406.30 percentage points. Which, honestly, feels like a math problem designed to induce panic.
Tango Therapeutics: The Basics (For Those of Us Who Didn’t Major in Biology)
Tango Therapeutics, in case you were wondering, isn’t a dance studio. They’re a clinical-stage biotech company. They’re developing cancer therapies, specifically targeting cancers with MTAP deletions, BRCA-mutant, and STK11-mutant cancers. It’s complicated. They also have a partnership with Gilead Sciences (GILD), which, if you’ve seen any commercials lately, is a very big deal.
Here’s a handy-dandy table of key metrics, because numbers are comforting (to some people):
| Metric | Value |
|---|---|
| Price (as of market close 2/17/26) | $12.80 |
| Market capitalization | $1.41 billion |
| Revenue (TTM) | $66.50 million |
| Net income (TTM) | ($100.52 million) |
So, Should You Invest? (I’m Not a Financial Advisor, Obviously)
Look, biotech stocks are…a mood. They’re volatile. One good clinical trial result and you’re practically Jeff Bezos. One bad result and…well, let’s not talk about it. It’s like dating. High highs, low lows, and a lot of awkward silences. If you’re risk-averse, maybe stick to index funds. Or, you know, a really good mattress.
If you must dabble in biotech, consider an ETF. The iShares Biotech ETF (IBB) is up about 28% over the last year. It’s not going to make you a billionaire overnight, but it’s less likely to give you a heart attack. Plus, it has a dividend yield of 0.2%, which is basically free money. Or enough to buy a slightly fancier coffee.
Ultimately, investing is a personal decision. Do your research, talk to a financial advisor (seriously, do it), and don’t invest more than you can afford to lose. And remember, even the smartest investors are just guessing most of the time. It’s chaos. Beautiful, terrifying chaos.
Read More
- Gold Rate Forecast
- Top 15 Insanely Popular Android Games
- 4 Reasons to Buy Interactive Brokers Stock Like There’s No Tomorrow
- Did Alan Cumming Reveal Comic-Accurate Costume for AVENGERS: DOOMSDAY?
- EUR UAH PREDICTION
- DOT PREDICTION. DOT cryptocurrency
- Silver Rate Forecast
- ELESTRALS AWAKENED Blends Mythology and POKÉMON (Exclusive Look)
- Core Scientific’s Merger Meltdown: A Gogolian Tale
- New ‘Donkey Kong’ Movie Reportedly in the Works with Possible Release Date
2026-03-05 02:22